PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsVolasertib
Volasertib
Volasertib is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against serine/threonine-protein kinase PLK1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
26 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeukemiaD007938—C95921——12
Myeloid leukemia acuteD015470—C92.0521——8
Myeloid leukemiaD007951—C92421——7
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8091———10
Myelodysplastic syndromesD009190—D4631———4
PreleukemiaD011289——31———4
SyndromeD013577——31———4
Non-small-cell lung carcinomaD002289———1———1
Ovarian neoplasmsD010051EFO_0003893C56—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Myelomonocytic leukemia chronicD015477—C93.12————2
Myelomonocytic leukemia juvenileD054429—C93.31————1
Precursor cell lymphoblastic leukemia-lymphomaD054198——1————1
Lymphoid leukemiaD007945—C911————1
Megakaryoblastic leukemia acuteD007947—C94.21————1
Monocytic leukemia acuteD007948——1————1
Myelomonocytic leukemia acuteD015479—C92.51————1
Erythroblastic leukemia acuteD004915EFO_1001257C94.01————1
LymphomaD008223—C85.91————1
T-cell lymphomaD016399——1————1
Show 2 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameVolasertib
INNvolasertib
Description
Volasertib (also known as BI 6727) is an experimental small molecule inhibitor of the PLK1 (polo-like kinase 1) protein being developed by Boehringer Ingelheim for use as an anti-cancer agent. Volasertib is the second in a novel class of drugs called dihydropteridinone derivatives.
Classification
Small molecule
Drug classserine/threonine kinase inhibitors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@@H]1C(=O)N(C)c2cnc(Nc3ccc(C(=O)N[C@H]4CC[C@H](N5CCN(CC6CC6)CC5)CC4)cc3OC)nc2N1C(C)C
Identifiers
PDB—
CAS-ID755038-54-1
RxCUI—
ChEMBL IDCHEMBL1233528
ChEBI ID—
PubChem CID—
DrugBankDB12062
UNII ID6EM57086EA (ChemIDplus, GSRS)
Target
Agency Approved
PLK1
PLK1
Organism
Homo sapiens
Gene name
PLK1
Gene synonyms
PLK
NCBI Gene ID
Protein name
serine/threonine-protein kinase PLK1
Protein synonyms
cell cycle regulated protein kinase, PLK-1, polo (Drosophia)-like kinase, Polo-like kinase 1, Serine/threonine-protein kinase 13, STPK13
Uniprot ID
Mouse ortholog
Plk1 (18817)
serine/threonine-protein kinase PLK1 (Q07832)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 1,103 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
13 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use